Videos

Blake K Williamson MD, MPH, MS, reviews a case of a 39-year-old female with high myopia and astigmatism seeking surgical refractive correction.

Blake K Williamson MD, MPH, MS, evaluates surgical correction options for a patient with low myopia and astigmatism and describes how phakic intraocular lens (IOL) implant can be a preferable option even in low myopia.

Blake K Williamson MD, MPH, MS, presents a case of a 36-year-old male patient with low myopia and astigmatism seeking surgical refractive correction.

In a conversation with David Hutton of Ophthalmology Times®, Ferhina S. Ali, MD, MPH, discussed the real world use of faricimab in the IRIS Registry during a presentation this week at Hawaiian Eye in Kauai Hawaii, focusing on the use of faricimab for the treatment of neovascular AMD and diabetic macular edema.

Daniel F Kiernan, MD, FACS, discusses the use of anti-inflammatory treatment when experiencing sub-optimal response with anti-VEGF therapy in DME.

Daniel F Kiernan, MD, FACS, reviews a case of a 49-year-old man with DME with extensive edema and high-risk proliferative diabetic retinopathy (PDR).

Daniel F Kiernan, MD, FACS, shares impressions of a patient case, focusing on challenges in access to care, and implementing treat and extend strategy in DME.

Daniel F Kiernan, MD, FACS, describes a case of a 62-year-old-man with diabetic macular edema (DME) and nonproliferative diabetic retinopathy (NPDR).

Denise Visco, MD, MBA, discusses takeaway points from patient case #2 for post-operative inflammation management for routine cataract surgery.

Denise Visco, MD, MBA, discusses takeaway points from patient case #1 for post-operative inflammation management for routine cataract surgery.

Denise Visco, MD, MBA, reviews Inflammation management in a 68-year-old patient following routine cataract surgery.

Daniel F Kiernan, MD, FACS, discusses idiosyncratic biologic response to anti-VEGF treatment in a patient with neovascular AMD.

Daniel F Kiernan, MD, FACS, reviews the case of an 83-year-old male patient with neovascular AMD.

Daniel F Kiernan, MD, FACS, discusses impressions and key takeaways from a neovascular AMD patient case, focusing on treatment intervals.

Daniel F Kiernan, MD, FACS, provides an overview of a patient case of a 79-year-old female with neovascular AMD.

On this week's episode of the NeuroOp Guru video blog, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Thymectomy in Ocular Myasthenia Gravis, Yes or No?

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss whether lumbar puncture should be required to diagnose every patient with idiopathic intracranial hypertension.

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Jay Pepose, MD, PhD. presented Incorporating "Topical Therapy in the Treatment of Presbyopia" at EyeCon 2022 in Marco Island, Florida.

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

The company is rolling out the Biovance 3L ocular tri-layer human amniotic membrane.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.